Syndax Pharmaceuticals (SNDX) Net Equity Issued and Repurchased (2015 - 2023)

Syndax Pharmaceuticals' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $216.0 million for Q4 2023.

• In Q4 2023, Net Equity Issued and Repurchased rose 33.31% year-over-year to $216.0 million; the TTM figure through Dec 2023 stood at $378.0 million (up 55.41% YoY), while the FY2023 annual figure was $216.0 million, up 1011.74% from the prior year.
• Net Equity Issued and Repurchased for Q4 2023 stood at $216.0 million, up from $162.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $216.0 million in Q4 2023, with the low at -$69.9 million in Q2 2021.
• The 5-year median for Net Equity Issued and Repurchased is $54.9 million (2020), against an average of $59.7 million.
• The sharpest annual moves came in 2019 and 2020: Net Equity Issued and Repurchased sank 538.17% in 2019, then soared 359570.0% in 2020.
• Syndax Pharmaceuticals' Net Equity Issued and Repurchased stood at -$26.5 million in 2019, then jumped by 608.49% to $135.0 million in 2020, then sank by 39.85% to $81.2 million in 2021, then jumped by 99.51% to $162.0 million in 2022, then surged by 33.31% to $216.0 million in 2023.
• Business Quant data shows SNDX's Net Equity Issued and Repurchased at $216.0 million in Q4 2023, $162.0 million in Q4 2022, and $81.2 million in Q4 2021.